Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma

Fig. 2

IQS019 impairs constitutive phosphorylation of Syk, Lyn and Btk tyrosine kinases in malignant B cells. a UPN-1, DOHH-2, OCI-LY10, and JVM-13 cells (6 x 106) were treated with increasing concentrations of IQS019 for 6 h, followed by Western Blot detection of phospho(p)-Syk, and p-Lyn, using β- actin as a loading control. Shown is a representative experiment from two replicates. b Flow cytometry analysis of p-Btk levels in cell lines treated as before. A PE-labeled mouse IgG1 κ was used as an isotype control (grey filled histogram). Indicated are the relative median fluorescence intensity (r) values observed after treatment with 5 μM IQS019 (grey curves), and referred to control untreated cells (black curves)

Back to article page